Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

This study has been terminated.
Sponsor:
Information provided by:
Chiron Corporation
ClinicalTrials.gov Identifier:
NCT00051688
First received: January 15, 2003
Last updated: July 10, 2006
Last verified: July 2006

January 15, 2003
July 10, 2006
June 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00051688 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer
Not Provided

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Not Provided
Interventional
Phase 2
Primary Purpose: Treatment
Colorectal Neoplasms
  • Drug: tezacitabine
  • Drug: oxaliplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
August 2004
Not Provided
  • Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy.
  • Patients must have at least one measurable tumor.
  • Patients may not have received prior treatment with oxaliplatin.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00051688
TEZ101
Not Provided
Not Provided
Chiron Corporation
Not Provided
Not Provided
Chiron Corporation
July 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP